IRCT201012295496N1已完成1 期
Assessing the effects of not using maintnance dose o atracurium dring open hear sugery in Coronary Artery Bypass Graft patiants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Inclusion criterion: 18-75y old patients planned to go under Coronary Artery Bypass Graft surgery.
- •Exclusion criteria: myopathy; neuropathy; sever pulmonary or renal disease; emergency surgery and opium addiction
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Safety Evaluation of the Maintenance treatment of Sorafenib in Hepatocellular carcinoma patients with Tumor thrombus after palliative surgeryTo evaluate the safety of sorafenib as a maintenance therapy after the surgical resection of hepatocellular carcinoma (HCC) with macroscopic vascular invasion (Vp, Vv, B).JPRN-UMIN000005910Tokyo University Hospital12
已完成
不适用
Examination of the remission maintenance effect by low dose etanercept after clinical remission in the rheumatoid arthritis.Rheumatoid ArthritisJPRN-UMIN000013362Takarazuka city hospital60
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’slymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL(Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma,marginal zone lymphoma), according to the WHO classificationsystem.MedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000013103EUCTR2010-023407-95-DEF. Hoffmann-La Roche Ltd700
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.EUCTR2010-023407-95-ATF. Hoffmann-La Roche Ltd700
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’s lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system.MedDRA version: 20.0 Level: LLT Classification code 10067070 Term: Follicular B-cell non-Hodgkin's lymphoma System Organ Class: 100000013103EUCTR2010-023407-95-GBF. Hoffmann-La Roche Ltd692